The present invention relates to a clear liquid ophthalmic composition comprising as the active ingredient a Spirulina platensis full extract and suitable liquid carriers and solubilising excipients. The invention also relates to a viscous liquid composition comprising an aqueous extract of spirulina platensis and to the use of said compositions in the treatment of several eye diseases.

The present invention relates to a clear liquid ophthalmic composition comprising as the active ingredient a Spirulina platensis full extract and suitable liquid carriers and solubilising excipients. The invention also relates to a viscous liquid composition comprising an aqueous extract of spirulina platensis and to the use of said compositions in the treatment of several eye diseases.

This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.

This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.

Products, systems and methods are disclosed for lowering the concentrations of at least one of preservatives and fibrils in a liquid insulin composition. One method comprises replacing at least a portion of at least one of phenol and m-cresol with at least one of cyclodextrins, cyclodextrin polymers, cyclodextrin beads, and an ion exchange resin.

Products, systems and methods are disclosed for lowering the concentrations of at least one of preservatives and fibrils in a liquid insulin composition. One method comprises replacing at least a portion of at least one of phenol and m-cresol with at least one of cyclodextrins, cyclodextrin polymers, cyclodextrin beads, and an ion exchange resin.

A fatty acid based composition for treatment and/or prevention of enveloped-virus related infections by administering fatty acid based compositions. The present invention further provides a free fatty acid based sprayable composition to prevent and/or treatment of SARS-Virus related infections. The fatty acids used in the present invention are Linoleic acid (LA), α-linolenic acid (ALA) and gamma-linolenic acid (GLA). In a preferred embodiment, we propose that topical administration of naturally occurring fatty acids in an optimal formulation may be beneficial in the prophylaxis of respiratory enveloped viruses and in particular the lipid-rich SARS-CoV-2 virus. This could be administered via nasal and/or oral route. The composition comprises at least one fatty acid, a suitable carrier, preservative, cosolvents and surfactants and/or cyclodextrin used as an excipient that may also enhance anti-viral properties.

A fatty acid based composition for treatment and/or prevention of enveloped-virus related infections by administering fatty acid based compositions. The present invention further provides a free fatty acid based sprayable composition to prevent and/or treatment of SARS-Virus related infections. The fatty acids used in the present invention are Linoleic acid (LA), α-linolenic acid (ALA) and gamma-linolenic acid (GLA). In a preferred embodiment, we propose that topical administration of naturally occurring fatty acids in an optimal formulation may be beneficial in the prophylaxis of respiratory enveloped viruses and in particular the lipid-rich SARS-CoV-2 virus. This could be administered via nasal and/or oral route. The composition comprises at least one fatty acid, a suitable carrier, preservative, cosolvents and surfactants and/or cyclodextrin used as an excipient that may also enhance anti-viral properties.

The present invention relates to methods for preventing, reducing, or treating the incidence and/or severity of a disorder caused by stress-induced cellular damage in the ear of a subject, such as vestibular disorders, hearing impairment, and conditions related to hair cell degeneration or death. Specifically, this invention pertains to formulations comprising probucol or a probucol ester, a bioavailability-enhancing compound comprising a bile acid, and optionally a carrier. The administration of these formulations can treat hearing loss and/or hair cell degeneration or death.

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.